EXAI
vs
S&P 500
EXAI
S&P 500
Over the past 12 months, EXAI has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +15% growth.
Stocks Performance
EXAI vs S&P 500
Performance Gap
EXAI vs S&P 500
Performance By Year
EXAI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Exscientia PLC
Glance View
Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.
